Applying existing ethical principles to personal medicine

Internet Journal of Law, Healthcare and Ethics

Volumn 6, Issue 1, 2009, Pages

  Jamie Cuticchia, A ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

Ethics; Genetics; Human genome project; Personal medicine; Pharmacogenomics

Indexed keywords

EID: 77749310146     PISSN: None     EISSN: 15288250     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Mendel, G: Versuche über Plflanzenhybriden. Verhandlungen des naturforschenden Vereines 3-47 (1865).
2. Collins, FS, M Morgan,A Patrinos: The Human Genome Project: lessons from large-scale biology. Science 300, 286-90 (2003).
3. Watson, JD: The human genome project: past, present, and future. Science 248, 44-9 (1990).
4. Venter, JC, MD Adams, EW Myers et al.: The sequence of the human genome. Science 291, 1304-51 (2001).
5. Lander, ES, LM Linton, B Birren et al.: Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
6. Bonicke R, Oe: The relation of excertory isoniazid levels to therapeudic results. Klin. Wochernschr. 33, 803-806 (1959).
7. Renegar, G, CJ Webster, S Stuerzebecher et al.: Returning genetic research results to individuals: points-to-consider. Bioethics 20, 24-36 (2006).
8. Meadows, M: FDA approves heart drug for black patients. FDA Consum 39, 8-9 (2005).
9. Brody, H,LM Hunt: BiDil: assessing a race-based pharmaceutical. Ann Fam Med 4, 556-60 (2006).
10. Carlson, RJ: The case of BiDil: a policy commentary on race and genetics.Health Aff (Millwood) Suppl Web Exclusives, W5-464-8 (2005).
11. Kahn, J: Race, pharmacogenomics, and marketing: putting BiDil in context. Am J Bioeth 6, W1-5 (2006).
12. Sankar, P,J Kahn: BiDil: race medicine or race marketing? Health Aff (Millwood) Suppl Web Exclusives, W5-455-63 (2005)
13. Consortium, H: A haplotype map of the human genome. Nature 437, 1299-320 (2005).
14. Pharmacogenomic Data Submissions, in 24 Biotechnology Law Reports. 2005, FDA.
15. Thomas, SM: Society and ethics - the genetics of disease. Curr Opin Genet Dev 14, 287-91 (2004).
16. Smith, W: Culture of Death: The Assault on Medical Ethics in America. 2001, San Francisco: Encounter Books.
17. Gurwitz, D, JE Lunshof,RB Altman: A call for the creation of personalized medicine databases. Nat Rev Drug Discov 5, 23-6 (2006).
18. Lee, SS: Racializing drug design: implications of pharmacogenomics for health disparities. Am J Public Health 95, 2133-8 (2005).
19. Festin, P: The regulatory, economic, and privacy implications of pharmacogenomics. Virginia Journal of Law & Technology 10, 1-40 (2005).
20. Goodwin, M: Race as Proxy in Law and Society: Emerging Issues in Race and the Law. DePaul Law Review 53, 931-941 (2004).
21. Breckenridge, A, K Lindpaintner, P Lipton, H McLeod, M Rothstein,H Wallace: Pharmacogenetics: ethical problems and solutions. Nat Rev Genet 5, 676-80 (2004).
22. Sadee's, W: Pharmacogenomics. Interview by Clare Thompson. Bmj 319, 1286 (1999).